Press Releases
16/06/2006
NeuTec Pharma completes recruitment in phase III trial for MRSA drug, Aurograb®
07/06/2006
Novartis
06/06/2006
Holding announcement
20/04/2006
Leading US Journal Publishes Mycograb® Trial Results
27/03/2006
NeuTec Pharma plc Interim Results
06/11/2005
Bob Nolan Director Shareholding 6 Dec 05
10/10/2005
Preliminary Results for the Year Ended 30 June 2005
16/9/2005
Notification of Preliminary Results
14/3/2005
Interim Results for the Six Months Ended 31 December 2004
18/1/2005
Mycograb - Initiation of a Programme for Compassionate Use
29/11/2004
NeuTec signs Manufacturing Partner for Mycograb
13/10/2004
Commercial Development Appointment
16/8/2004
Result of EGM and AGM
13/8/2004
Placing and Open Offer Result
23/7/2004
Proposed placing and open offer to raise £25.8 million and proposed adoption of an LTIP
12/7/2004
Preliminary Results for the Year Ended 30 June 2004
5/5/2004
NeuTec Pharma commences phase III trials for MRSA drug, Aurograb
11/3/2004
Interim Results for the Six Months Ended 31 December 2003
3/3/2004
NeuTec Pharma announce date for interim results
30/1/2004
Mycograb® Completion of Phase II Trial
13/11/2003
Mycograb(R) Clinical Trial: EMEA Update
14/10/2003
Preliminary Results for the Year Ended 30 June 2003
14/10/2003
NeuTec announces changes to the Board
9/10/2003
Notification of Results
6/10/2003
NeuTec Pharma to seek development partners for Mycograb(R)
13/6/2003
NeuTec Pharma announces encouraging phase IIb data on its MRSA drug, Aurograb
5/3/2003
Interim Results for the Six Months Ended 31 December 2002
5/2/2003
Submission of an Investigational New Drug application for Mycograb®
13/1/2003
Update on MRSA Aurograb® Phase IIa trial – safety data
6/12/2002
Update on Mycograb® Phase II trial
8/10/2002
Preliminary Results for the Year Ended 30 June 2002
25/3/2002
NeuTec Pharma plc Interim report
14/2/2002
Publication of AIM Admission Document and Pricing